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1. Introduction
Head and neck cancer (HNC) is the sixth most common cancer worldwide,[1] which includes
cancers of the aerodigestive tract, including lip, oral cavity, nasal cavity, paranasal sinuses,
pharynx, larynx, oropharynx, hypopharynx, salivary glands, and local lymph nodes.[2] More
than 90% of these are head and neck squamous cell carcinomas (HNSCC), arising from the
mucosal lining in these regions.[3, 4]
Although oral squamous cell carcinomas (OSCC) can arise de novo from clinically normal
appearing mucosa,[5, 6] they are typically preceded by clinically apparent changes in the
tissue, termed oral potentially malignant lesions (OPML) and include leukoplakia, erythro‐
plakia, oral submucous fibrosis, oral lichen planus and actinic keratosis.[7-9] Oral epithelial
dysplasia (OED) is a histopathologic diagnosis that describes this tissue transformation and is
characterised by cellular and morphological changes similar to those in OSCC but are limited
to epithelial cells and remain non-invasive, hence termed premalignant or potentially malig‐
nant.[10] The histological grading system developed by the World Health Organisation is used
widely to describe the degree of OED in oral mucosa – mild, moderate and severe dysplasia,
and carcinoma in situ.[10] The histopathological diagnosis of OED, and its severity as inter‐
preted by pathologists, is used as a predictor of a lesion’s risk of malignant transformation,
and also the type of intervention required – surgical treatment or watchful waiting.[11]
However, a recent study found that this system was not useful for predicting patient outcomes
or determining management strategies and recommended definitive treatment of all OED until
a more reliable progression/transformation system is developed.[10] In addition, the presence
of a non-homogeneous mucosal lesion has been shown to be a significant independent clinical
indicator of underlying OED.[8]
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Despite the reported transformation rate of 31.4% of OPMLs to OSCC,[12] clinical and
histological characteristics have limited potential as predictors of transformation and do not
aid in early diagnosis of HNSCC.[5, 13] It has been shown that as many as 50% of HNSCCs
may arise from apparently clinically normal mucosa, thus posing an inherent diagnostic
challenge.[5, 6] Although it is established that OPML and OED are statistically more likely to
progress to cancer, the actual underlying mechanisms are poorly understood, and it is not
inevitable that a dysplastic lesion will progress to cancer.[5, 6] Thus upon clinical diagnosis of
HNSCC, the disease staging is often advanced with worsened prognosis.[5, 11]
The diagnostic process for OPML, OED or suspected HNSCC involves visual and tactile
inspection using white light and other adjunctive visual aids, histopathological assessment of
a biopsy sample, and one or more diagnostic imaging methods by radiography or molecular
methods (positron emission tomography (PET), computerised tomography (CT), magnetic
resonance imaging (MRI)).[14] All these approaches are necessary to aid in accurate tumour
staging which directs therapeutic planning, and have to overcome significant challenges
including delineation of tumour volume and accurate location, cervical lymph node involve‐
ment, distant metastasis, and presence of second primary tumours.[15] The main treatment
modality for HNSCC, determined at the stage of diagnosis, continues to be surgical resection
in combination with chemoradiotherapy depending on anatomical location.[16] Stratified
treatment approaches exist based on HPV status. Newer treatment modalities involve drug/
molecular targets used in conjunction with radionuclide tracers leading to personalised
medicine.[14, 17] However, despite advanced techniques for early detection and management
of HNSCC, the 5-year survival rate of smoking associated HNSCC is still 30-50%, with
survivors experiencing poor quality of life.[4, 18] Overall, patients with advanced disease
continue to have a poor prognosis and high locoregional and distant recurrences,[19] sup‐
porting the need for hybrid technologies both pre-, post-, and during surgery to attain
maximum information in minimum time.
2. Surgical margin assessment
The aim of cancer surgery is to remove as much diseased tissue and retain as much healthy
tissue as possible.[20] The key issue with surgical management of OSCC is predicting the risk
of locoregional relapse, reported to occur in up to 20% of cases, accounting for ongoing modest
survival rates.[21-24] One key predictor of locoregional relapse is the presence of carcinoma
in or close to the surgical margins of the primary tumour, which is currently not reliably
possible despite surgeon’s conventional gross assessment (limited to white light tissue
reflectance assessing colour and texture) and thorough histopathological examination, as
relapse can occur in cases with clear margins.[19, 20, 24] Histopathological examination reports
margins as clean/clear (>5 mm between carcinoma and margin), involved (carcinoma exists
within 1 mm of the margin), or close (carcinoma exists between 1 to 5 mm from the margin).
[24-26] Even though this method has a reported accuracy ratio of >95%, around 30% of patients
with histologically negative margins undergo treatment failure raising concerns about its
sensitivity.[19, 27-30] In addition, intraoperative histopathological assessment relies on the
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quality of samples and degree of sampling, extends the time of operation and yields incomplete
results.[20]
While in some cases histopathological examination shows tumour cells in the surgical margins
thus implying that residual tumour cells could still exist in patients, most patients with local
relapse have histologically clear surgical margins.[24] In these cases, relapse may be due to
minimal residual disease (MRD) or field cancerisation.[24] In the case of MRD, small clusters
of histopathologically undetectable tumour cells proliferate leading to local recurrence.[24]
The field cancerisation model describes a field of premalignant epithelium, which may be
rather expansive due to the process of lateral cancerisation, containing preneoplastic cells from
which the primary carcinoma may have developed, and second primary tumours (SPT) can
develop, following additional genetic hits.[24, 31] Differentiation between SPT and local
recurrence due to MRD must be made where possible in order to determine appropriate
therapeutic measures – while the latter may be treated with post-surgical radiotherapy or
resection, treatment of the former is more complicated.[24] Surgery is not feasible due to the
large extent of disease and radiotherapy may even be contraindicated as it could aid in the
progression of preneoplastic cells into neoplasia, and thus more intensive surveillance during
follow-up may be the best option.[24]
Most studies demonstrate an association between involved or close margins and a worse
prognosis,[21, 32] with involved margins resulting in shorter disease-free survival,[21, 23, 32]
and shorter overall survival.[33] The presence of close margins has prognostic significance,
with a recent study finding margins at a cut-off of ≤1.6mm from the tumour to be prognostic
of shorter disease-free survival and shorter overall survival.[32] However, molecular changes
indicating early tumour development have been demonstrated in surgical margins of tumours
from the larynx, pharynx, and oral cavity considered histologically ‘normal’.[23, 34, 35] The
rate of local recurrence (and thus failure of treatment) even in margins diagnosed as tumour-
free is quoted in studies to be anywhere from 6.9-22%.[36]
It has been hypothesized that the majority of genetic alterations may occur during the early
cancer progression process and can precede the observation of certain cytological changes.[37]
It is thus believed that if given a reliable set of molecular or genetic biomarkers of epithelial
transition/progression to malignancy, the subsequent removal of the altered tissue may
prevent the future development of malignancy at that site.[38, 39] Such molecular biomarkers
may also be used to assess the margins of tumours subsequent to surgical resection,[24, 40]
allowing a means of objective assessment which may detect MRD, and predict potential for
local recurrence in the surrounding tissues. Furthermore, molecular studies on genetic markers
have shown there is a clonal relationship between the primary tumour and premalignant
epithelium adjacent to the tumour,[24] suggesting that molecular analysis of histologically
negative surgical margins may be a more sensitive method for detecting malignant trans‐
formed cells.[19] Ultimately we would like to propose a shift from conventional histopatho‐
logical assessment of surgical margins to molecular analysis, either through laboratory testing
or imaging techniques.
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3. Biomarkers in HNSCC
Since there is a need to reconsider methods of surgical margin assessment during SCC
resection, margins should not only be examined macroscopically and microscopically, but also
at a molecular level for dysregulated gene expression, which is also applicable in the diagnosis
of OED and OPML. It is currently accepted that genetic and epigenetic changes within a clonal
population of cells drives carcinogenesis by influencing oncogenes and tumour suppressor
genes (TSG).[41-43]
Current modelling postulates that the development of cancer is driven by the accumulation of
genetic and epigenetic changes within a clonal population of cells.[44] These genotypic
alterations can affect hundreds of genes, leading to phenotypic changes in critical cellular
functions such as resistance to cell death, increased proliferation, induction of angiogenesis,
and the ability to invade and metastasize.[45] The mechanisms underlying these genetic and
epigenetic aberrations can include genomic instability through chromosomal rearrangement,
amplification, deletion, methylation, or mutation.[45]
These genetic alterations have been shown to contribute directly to cancer development and
progression, and have a direct effect upon oncogenes and TSGs as well as the phenotypes they
regulate.[41-43] There has been considerable investigation into the genotypic and phenotypic
alterations observed in HNC,[42] and many studies have attempted to identify the genetic and
molecular aberrations occurring in HNC surgical margins as a means of predicting local
recurrence and relapse.
De Carvalho et al. examined 55 HNSCC patients undergoing operative therapy with histolog‐
ically negative surgical margins and found 36.4% of these patients (20/55) showed overex‐
pression of one of three genes they reported to being overexpressed in tumour samples –
MMP9, EPCAM and PTHLH, with MMP9 overexpression correlating with the risk of devel‐
oping SPT.[19] Santhi et al. showed that both cytoplasmic and nuclear NF-κB proteins had a
significant negative correlation from tumour to surgical margin to extra margin (2 cm away
from the actual surgical margin), with COX-2 paralleling its expression, suggesting that these
molecules are involved in tumour progression and may be used as markers in assessing MRD.
[46] In a later study, they compared the expression microRNAs (miRs) in oral tumour pro‐
gression and oral surgical margins.[47] They reported a decreased expression of I-miR-125a,
I-miR-184, and I-miR-16 and an increased expression of I-miR-96 in the progression from
normal mucosa to OED to OSCC, supported by the same pattern of expression retrogressing
from extra margin samples to margin samples to tumour samples.[47]
Potential molecular markers for OSCC or OED include: protein markers (e.g. TP53,[35, 48-53]
MMP9,[54] CDKN2A (p16),[49, 55-57] EIF4E[58), epigenetic markers (promoter hypermethylation),
{Sinha, 2009 #1258, 59-61] microRNA expression (e.g. miR-16, miR-125a, miR-184),[47] DNA
copy number changes, [50, 62-65] and loss of heterozygosity (e.g. 3p, 9p, 13q, 11q, 17p).[63,
66-68] Table 1 summarises studies that have investigated molecular markers with the potential
to predict local relapse. Table 2 details the list of studies investigating the performance of
molecular markers in HNSCC surgical margin analysis using a case (with relapse) and control
(without local relapse) approach, with the development of local relapse being the end-point.
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Study Marker (analysis
method)
Patients and
Tumours
Samples studied Results (number of
positive/total)
Notes
Jin et al.[292] TP53 mutation
(PCR-SSCP)
Laryngeal
carcinoma
(n = 20)
Tumour-adjacent tissue
histologically normal
5/20
Cruz et al.[48] TP53 mutation
(IHC)
OSCC
(n = 42)
Tumour-adjacent tissue
non-malignant mucosa
7/42
Tunca et al.[51] TP53 mutation
(PCR-SSCP and
sequencing)
HNSCC
(n = 15)
Surgical margin tissue 5/15
Van der Toorn et
al.[293]
TP53 mutation
(IHC)
OSCC
(n = 20)
Tumour-free surgical
margin
11/20
Blide et al.[49] TP53 mutation,
CDKN2A (p16),
CHEK2,
LAMA5 (via IHC)
OSCC
(n = 16)
Tumour-free surgical
margin
12/16 (TP53)
11/16 (p16)
1/16 (CHEK2)
0/16 (LAMA5)
Shin et al.[294] TP53 mutation
(IHC)
HNSCC
(n = 31)
Tumour-adjacent
normal epithelium
6/31
Van Houten et al.
[94]
TP53 mutation
(IHC)
HNSCC
(n = 30)
Tumour-free surgical
margin
19/30 Only margin
samples with TP53
mutation in tumour
were investigated
Nathan et al.[54] TP53 mutation,
4E,
MMP-9
(via IHC)
HNSCC
(n = 52)
Tumour-free surgical
margin
- 23/52 (TP53)
- 27/52 (4E)
- 28/52 (MMP-9)
Tabor et al.[82] Microsatellite
(LOH)
HNSCC
(n = 28)
- Tumour-adjacent non-
malignant mucosa
samples (n = 140)
- Tumour-free surgical
margins
(n = 42)
- 10/28
- 7/28
Szukala et al.[295] Microsatellite
(LOH at 13q)
Laryngeal
carcinoma
(n = 65)
Cancer-free surgical
margin
8-20/65
Poh et al.[68] Microsatellite
(LOH at 3p and 9p)
OSCC
(n = 20)
Tumour-adjacent tissue,
cancer free (n = 32)
15/32
Breiger et al.[67] Microsatellite at
3q26
HNSCC
(n = 20)
- Biopsy 1cm from
tumour
(n = 20)
- 4/20
- 3/20
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Study Marker (analysis
method)
Patients and
Tumours
Samples studied Results (number of
positive/total)
Notes
- Biopsy 2cm from
tumour
(n = 20)
Bremmer et al.[63] Microsatellite
(LOH at 3p, 9p, 11q
and 17p),
DNA ploidy,
MLPA
HNSCC
(n = 10)
Cancer-free surgical
margin
- 10/10
- 4/10
- 10/10
Only margins with
TP53 mutations
were analysed
Martone et al.[55] Promoter
hypermethylation
of MGMT,
CDKN2A (p16),
DAPK1
HNSCC
(n = 11)
Cancer-free surgical
margin
5/11 (MGMT)
3/11 (CDKN2A
(p16))
8/11 (DAPK1)
Goldenberg et al.
[34]
Promoter
hypermethylation
MGMT and
CDKN2A (p16)
HNSCC
(n = 6)
Surgical margins 3/6 Intraoperative
margin analysis
Wong et al.[57] Promoter-
methylation
CDKN2A (p16)
and p15
HNSCC
(n = 73)
Tumour-adjacent
mucosa histologically
normal
(n = 29)
5/29 (CDKN2A
(p16))
18/29 (p15)
Supic et al.[61] Promoter
hypermethylation
of p16,
DAPK,
RASSF1A,
APC,
WIF1,
RUNX3,
E-cad,
MGMT,
hMLH1
OSCC
(n = 47)
Tumour-adjacent
mucosa histologically
normal
44/47 (any marker)
27/47 (p16)
14/47 (DAPK)
17/47 (RASSF1A)
6/47 (APC)
19/47 (WIF1)
11/47 (RUNX3)
6/47 (E-cad)
7/47 (MGMT)
6/47 (hMLH1)
Shaw et al.[296] Promoter
hypermethylation
of
p16,
CYGB (via PMA)
OSCC
(n = 20)
Deep margins
histologically tumour-
free
11/20 (p16)
17/20 (CYGB)
Possible
contamination from
adjacent tumour
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Study Marker (analysis
method)
Patients and
Tumours
Samples studied Results (number of
positive/total)
Notes
Roh et al.[60] Promoter
hypermethylation
of
p16,
DCC,
KIF1A,
EDNRB (via qMSP)
HNSCC
(n = 12)
Deep margins grossly
tumour-free
8/12 (any marker)
Kato et al.[72] Promoter
hypermethylation
of
p16,
MGMT (via MSP)
OSCC
(n = 51)
Tumour-adjacent
mucosa histologically
normal
(n = 22)
6/22 (p16)
9/22 (MGMT)
Barrera et al.[297] Chromosome
imbalance
(Interphase-FISH)
HNSCC
(n = 10)
Cell brushings of
clinically normal
tumour-adjacent
margins
10/10 Possible
contamination from
adjacent tumour
Voravud et al.
[298]
Chromosome
imbalance
(Interphase-FISH)
HNSCC
(n = 20)
Epithelium adjacent to
tumour, histologically
normal
8/20
Ott et al.[62] Chromosome
imbalance
(Interphase-FISH)
HNSCC
(n = 20)
Tumour-adjacent
margins
Most cases/20 (any
genomic change)
Various
chromosomes
targeted
Stafford et al.[64] Chromosome
imbalance (CGH)
HNSCC
(n = 19)
Clinically normal
tumour-adjacent
mucosa
0/19
Fabricius et al.
[299]
Telomerase (DNA-
PCR)
HNSCC
(n = 40)
Tumour margin biopsy 13/40
Preuss et al.[65] DNA Ploidy HNSCC
(n = 20)
- Biopsy 1cm from
tumour
(n = 20)
- Biopsy 2cm from
tumour
(n = 20)
Greater DNA
irregularity at 1cm
than 2cm
De Carvalho et al.
[19]
Expression of
PTHLH,
EPCAM,
MMP-9,
HNSCC
(n = 55)
Tumour-adjacent
mucosa histologically
normal
20/55 (any marker)
13/55 (MMP-9)
6/55 (EPCAM)
5/55 (PTHLH)
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Study Marker (analysis
method)
Patients and
Tumours
Samples studied Results (number of
positive/total)
Notes
Graveland et al.
[300]
LY6D (qRT-PCR) HNSCC
(n=55)
‘Clean’ or ‘close’ deep
margins histologically
tumour-free
12/55
Dasgupta et al.
[301]
Mitochondrial
DNA (mtDNA)
mutation
HNSCC
(n = 50)
Histologically normal
margins
(n = 24)
17/24 Only margins with
mtDNA mutation
in tumour were
assessed
Santhi et al.[47] microRNA
expression
OSCC
(n = 84)
- Surgical margin tissues
(histologically mild to
moderate dysplastic)
- Extra margin tissue
(histologically normal)
(n = 56)
- Increased
expression
(miR-125a, miR-184,
miR-16) in margin
vs. tumour
- Decreased
expression (miR-96)
in margin vs.
tumour
Table 1. Molecular markers at HNSCC surgical margins with potential to predict local relapse
Study Marker
(analysis method)
Patients
and margins
(Number of
patients with
positive
molecular
margins/total
patients)
Sensitivity
(positive
margins/
number of cases)
Specificity
(negative
margins/
number of
controls)
Significance Notes
Brennan et al.
[93]
TP53 mutation
(Sanger
sequencing)
HNSCC
(n = 30)
Evaluated
(n = 25)
Margins
(n = 72)
13/25 (48%) 5/5 (100%) 12/20 (60%) Yes
(KM-
logrank)
Van Houten et
al.[97]
TP53 mutation
(Sanger
sequencing)
HNSCC
(n = 179)
Evaluated
(n = 76)
Margins
(4 to 5 per
tumour, 3-4
superficial
50/76 (66%) 9/9 (100%) 25/62 (40%) Yes
(KM-
logrank)
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Study Marker
(analysis method)
Patients
and margins
(Number of
patients with
positive
molecular
margins/total
patients)
Sensitivity
(positive
margins/
number of cases)
Specificity
(negative
margins/
number of
controls)
Significance Notes
and 1 deep
mucosal
margin)
Bergshoeff et
al.[50]
TP53 mutation
(IHC),
Chromosome
instability (CIN)
(via Interphase-
FISH)
OSCC
(n = 20)
Evaluated
(n = 19)
8/19 (42%) 3/4 (75%) – TP53
4/4 (100%) - CIN
10/15 (67%) -
TP53
11/15 (73%) - CIN
No – TP53
(Fisher-exact
test)
Yes - CIN
(Fisher-exact
test)
Huang et al.
[302]
TP53 mutation
(Sanger
sequencing)
OSCC
(n = 58)
Evaluated
(n = 25)
16/25 (64%) 11/13 (85%) 7/12 (58%) Yes
(KM-
logrank)
Partridge et al.
[35]
TP53 mutation (p53
phage plaque
assay,
immunocytochemi
stry, FASAY)
OSCC
(n = 18)
Evaluated
(n = 11)
6/11 (55%) 4/5 (80%) 4/6 (67%) Not
performed
Nathan et al.
[110]
TP53 mutation
(IHC),
eIF4E (IHC)
Laryngeal
carcinomas
(n = 54)
6/54 (11%) -
TP53
32/54 (59%) –
EIF4
6/23 (26%) – TP53
21/25 (84%) –
EIF4
31/31 (100%) –
TP53
18/29 (82%) –
EIF4
Yes
(KM-
logrank)
Graveland et
al.[52]
TP53 mutation
(IHC),
LOH (PCR),
Ki-67 (IHC)
HNSCC
(n = 35)
17/35 (49%) -
LOH
11/16 (69%) –
LOH
(75%) – positive
TP53 staining
(62%) – positive
TP53 with >5%
total epithelium
positive
(62%) - LOH 9p
present
(88%) – LOH 9p
and/or >5% TP53
staining positive
6/19 (31%) – LOH
(47%) – positive
TP53 staining
(84%) – positive
TP53 with >5%
total epithelium
positive
(74%) - LOH 9p
present
(63%) – LOH 9p
and/or >5% TP53
staining positive
Yes - LOH
9p and/or
>5% TP53
staining
positive
(KM-
logrank)
No – Ki-67
(KM-
logrank)
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Study Marker
(analysis method)
Patients
and margins
(Number of
patients with
positive
molecular
margins/total
patients)
Sensitivity
(positive
margins/
number of cases)
Specificity
(negative
margins/
number of
controls)
Significance Notes
Pena Murillo
et al.[95]
TP53 mutation,
Ly-6D (qRT-PCR)
OSCC
(n = 142)
Evaluable
(n = 102)
Carcinoma-
free resection
margins
51/102 (50%) –
TP53
14/51 (27%) –
Ly-6D
(92%) – TP53
(42%) – Ly-6D
(70%) –
Combined TP53
and Ly-6D
(56%) – TP53
(81%) – Ly-6D
(70%) –
Combined TP53
and Ly-6D
Yes – TP53
(KM-
logrank)
No – Ly-6D
(KM-
logrank)
46 cases received
post-op
radiotherapy
Only wild-type
TP53 positive
margins were
analysed for Ly-6D
Yi et al.[96] TP53 mutation,
Cyclin D1,
eIF4E (ISH)
Laryngeal
carcinoma
(n = 115)
47/115 (41%) –
TP53
34/115 (30%) -
D1
35/115 (30%) -
eIF4E
21/33 (64%) –
TP53
17/33 (51%) - D1
28/33 (85%) -
eIF4E
56/82 (68%) –
TP53
65/82 (79%) - D1
75/82 (91%) -
eIF4E
Yes
(Chi-square)
Nathan et al.
[58]
eIF4E (IHC) HNSCC
(n = 65)
36/65 (55%) 20/22 (91%) 27/43 (63%) Yes
(KM-
logrank)
Ogbureke et
al. [303]
Bone sialoprotein
(BSP),
Dentin
sialophosphoprotei
n (DSSP),
Osteopontin
(OPN),
MMP-9
(via IHC)
OSCC
(n = 20)
Surgical
margins
(histologically
negative)
(n = 200)
10/20 (50%) –
BSP
14/20 (70%) –
DSPP
14/20 (70%) –
OPN
16/20 (80%)
MMP-9
6/9 (67%) – BSP
8/9 (89%) – DSPP
7/9 (78%) – OPN
6/9 (67%) MMP-9
4/11 (36%) – BSP
6/11 (55%) –
DSPP
7/11 (64%) – OPN
10/10 (100%)
MMP-9
Yes
(KM-
logrank)
Reis et al. [304] 4-gene signature of
MMP-1,
COL4A1,
P4HA2,
THBS2
(via qRT-PCR)
OSCC
(n = 30)
Margins
(n = 136)
Not reported Not reported Not reported Yes
(KM-
logrank)
All four genes were
up-regulated in
margins of patients
with disease
recurrence
compared to those
without recurrence.
Monteobugnol
i et al. [305]
Ki-67 expression OSCC
(n = 42)
13/42 (30%) -
High Ki-67
values
2/4 (50%) - High
Ki-67 values
25/38 (65%) -
High Ki-67 values
Yes
(KM-
logrank)
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Study Marker
(analysis method)
Patients
and margins
(Number of
patients with
positive
molecular
margins/total
patients)
Sensitivity
(positive
margins/
number of cases)
Specificity
(negative
margins/
number of
controls)
Significance Notes
29/42 (69%) –
Low Ki-67
values
1/4 (25%) - Low
Ki-67 values
9/38 (24%) - Low
Ki-67 values
Sardi et al.[86] Microsatellite
analysis (MSI and
LOH)
HNSCC
(n = 41)
11/25 (44%) 7/8 (88%) 13/17 (76%) Yes
(KM-
logrank)
Temam et al.
[306]
Microsatellite
analysis (MSI)
HNSCC
(n = 76)
Evaluated
(n = 26)
Margins
(n = 113)
7/26 (27%) 5/5 (100%) 19/21 (90%) Yes
(KM-
logrank)
Handschel et
al.[307]
DNA ploidy HNSCC
(n = 40)
16/40 (40%) 14/20 (70%) 18/20 (90%) Not reported
Zhao et al.
[308]
CD44v6,
BIRC5 (survivin)
(via IHC)
Laryngeal
carcinoma
(n = 146)
Evaluated
(n = 112)
35/112 (31%)
CD44v6
44/112 (39%)
BIRC5
20/41 (49%)
CD44v6
26/41 (63%)
BIRC5
56/71 (79%)
CD44v6
53/71 (75%)
BIRC5
Yes
(univariate
cox-
proportional
hazard)
Schaaij-Visser
et al. [309]
KRT4 (cytokeratin
4),
CRNN (cornulin)
(via IHC)
HNSCC
(n = 46)
23/46 (50%)
23/46 (50%)
17/23 (74%)
16/23 (70%)
17/23 (74%)
16/23 (70%)
Yes
(KM-
logrank)
Sinha et al.[56] Methylation of
CDKN2A (p16)
OSCC
(n = 30)
13/30 (43%) 5/6 (67%) 16/24 (67%) Yes
(KM-
logrank)
Tan et al.[59] Methylation of
CDKN2A (p16,
CCNA1,
DCC
HNSCC
(n = 42)
Evaluated
(n = 27)
11/27 (41%) 5/5 (100%) 16/22 (73%) Yes
(KM-
logrank)
Table 2. Performance of molecular markers in HNSCC surgical margin analysis of patients with (cases) and without
(controls) local relapse [adapted and modified from Braakhuis et al.[24]
Contemporary Assessment and Management of Head and Neck Cancer Surgical Margins
http://dx.doi.org/10.5772/60066
85
3.1. Epigenetic events
Unlike genetic alterations, epigenetic changes are heritable and potentially reversible.[69]
Epigenetic changes refer to any heritable modifications in gene expression without alterations
of the DNA sequence; they occur more frequently than gene mutations and may persist for
the entire cell life and even for multiple generations.[43] The transcription of each gene may
change from high-level expression to complete silencing, depending on the influence of the
“epimutations” which interfere with the action of activators and suppressors on specific
promoters in the chromatin context.[41] Epigenetic inheritance includes DNA methylation,
histone modifications and RNA-mediated silencing.
Promoter hypermethylation is a well-documented mechanism for tumour-specific alteration
of suppressor gene activity in human malignancy, including head and neck cancer.[70] In
normal tissues, unmethylated cytosine is found in high densities in CpG islands; areas with
high concentration of cytosine and guanine that map close to a promoter region in 40% of
mammalian genes.[41] This unmethylated state is associated with a high rate of transcriptional
activity; vital for maintaining TSG levels. Where hypermethylation of TSG occurs (via the
enzyme DNA methyltransferase), stable transcriptional silencing of tumour suppressor
activity occurs.[42, 69]
Studies have shown that methylation of the p16INK4a gene is a frequent event in primary
HNC, with hypermethylation occurring in 50-73% of cases.[34, 71] In an analysis of 22 OSCC
cases where paired cancerous tissues and the surrounding normal mucosa were simultane‐
ously analysed, methylation of p16 and O6-methylguanine-DNA-methyltransferase (MGMT;
a gene which produces a DNA repair enzyme essential for removing adducts caused by
alkylating agents) were shown in 27-40% of specimen margins considered ‘normal’.[72] In a
recent study on the prognostic significance of tumour-related gene hypermethylation in
cancer-free surgical margins of OSCC, Supic et al. selected a number of genes involved in a
wide range of cellular processes for analysis.[61] These included cell cycle control (p16),
apoptosis (DAPK and RASSF1A), Wnt signalling (APC, WIF1 and RUNX3), cell–cell adhesion
(E-cad), and DNA repair (MGMT and hMLH1).[61] Results showed that whilst DNA hyper‐
methylation in histologically negative surgical margins is a frequent event, hypermethylation
of p16 did not have prognostic significance.[61] Sinha et al. found that patients with positive
molecular margins for p16 hypermethylation had a 6.3-fold increased risk of having local
recurrence compared to patients with negative margins.[56] However, positivity of margins
did not show any significant correlation with T classification, nodal status, histological
presence or status of marginal dysplasia, or any other patient or tumour parameter.[56]
However, in a recent systematic review and meta-analysis of literature, Rainsbury et al.
concluded that based on 6 studies analysed, significantly better overall survival rates was seen
in p16-positive oropharyngeal squamous cell carcinoma (OPSCC) tumours.[73] Differences in
methodologies and cut-off points for analysis between the studies remain a limitation for
analysis, and there remains inadequate evidence at this time to determine whether or not
hypermethylation of p16 can be used as a biomarker for use in determination of clear surgical
resection margins or to predict the risk of local relapse.
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3.2. Loss of heterozygosity
Loss of heterozygosity (LOH) may occur when one copy of a polymorphic marker with two
slightly different alleles is lost or amplified (allelic gain).[45] LOH in key chromosomal loci
represents one of the more promising markers; consistently being identified as a potentially
independent risk predictor, supported by data from several laboratories, including studies by
Sidransky, Califano, Mao, Hong, Lippman, and Lee.[12, 74-78]
Califano and Sidransky developed genetic progression models based on their studies of gene
alterations in squamous cell carcinoma of the head and neck.[79, 80] They reported LOH at
9p21, 3p and 17p13 in squamous hyperplasia, as well as LOH at 13q11, 13q21 and 14q31 in
dysplasia, with loss of chromosomal region 9p21 being the most common genetic alteration in
HNSCC (occurring in 70-80% of dysplastic lesions of the oral mucosa).[75, 79] Consensus has
emerged that LOH at 3p and 9p provides evidence of the accumulation of genetic damage in
potentially malignant lesions.[40, 81, 82] This has led to a number of investigations into the
predictive value of LOH at these specific chromosomal loci in malignant risk of low-grade
OED.[83-85] There is a general trend for lesions with greater disturbance in cellular architecture
and organization to harbor more genetic alterations at 3p and 9p, however this is not noted in
all studies. [40, 74, 76, 80]
Bremmer et al. implemented a range of genetic assays to screen for oral pre-malignant fields
in histologically ‘normal’ mucosa, and concluded that LOH may be a valuable screening tool
to detect oral pre-malignant fields in high risk patients.[63] The utility of LOH to evaluate risk
of local recurrence in surgical margins was also noted by Sardi et al.[86] However, a study by
Szukala et al. found no predictive value of LOH to determine risk of local relapse in laryngeal
cancer patients, with a low frequency of LOH detected in collected ‘clean’ margin samples.[66]
The predictive and prognostic capacity of LOH at 3p and 9p to predict risk of transition from
OED to malignancy has also been recently explored. A study by Zheng et al. in 2012 aimed to
prospectively validate their retrospective “2000 LOH progression model” proposed by Rosin
et al.[84, 87] Using a prospective cohort of 296 subjects with a histologic diagnosis of primary
mild/moderate dysplasia, the authors first validated their original model for predicting
progression to severe dysplasia, carcinoma in situ, or invasive cancer.[84, 88] High-risk (3p
and/or 9p LOH) lesions were found to have a 22.6-fold increased risk of progression when
compared with the low-risk (3p and 9p retention) lesions; findings consistent with the previous
study.[84, 87] By further refining their model with the inclusion of two further markers (4q
and 17p), prospective validation of the new model was performed. It demonstrated that low-
grade lesions showing retention of 9p had approximately a 5% risk of progression over 5 years
to severe dysplasia or more advanced disease.[87] This finding has important implications, as
it could suggest that individuals falling into this category might not require aggressive
treatment or monitoring despite having a histologic diagnosis of dysplasia. Conversely, a high-
progression rate (approximately 65%) for high-risk lesions was found, and would suggest that
this group should be aggressively monitored for clinical progression.[87]
From this study, a number of areas for future investigation arise. It is important to evaluate
the capacity of LOH to predict risk of progression within the immediate surrounding field and
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of secondary oral malignancy, given that a portion of HNSCC may not arise from the exact
site of the visually distinguished pre-malignancy.[85, 88]
Ultimately, comparison amongst existing studies is hindered by methodological differences,
adjustment for confounders, and controls. Whilst early evidence appears promising, the
clinical utility of LOH in 3p and 9p as a predictive tool to screen for progression of OED at
surgical resection margins still requires further long-term prospective validation and/or
investigation.[45, 84]
3.3. p53 family
p53 is a TSG located on chromosome 17p13, and plays a major role in cell-cycle progression,
cellular differentiation and DNA repair and apoptosis.[89, 90] Loss of p53 function impairs the
regulation of cell cycle arrest and apoptosis, thus altering the ability of cells to respond to stress
or damage (such as DNA damage, hypoxia, and oncogene activation).[89, 90] This can then
lead to genomic instability, and the accumulation of additional genetic alterations.[91] Loss of
p53 has long been implicated in early carcinogenesis, including HNSCC.[92]
Several studies have investigated the expression of p53 in HNSCC tumour resection margins.
[24, 49] Three groups have used p53 mutation-specific probes to detect aberrant cells in the
resection margins,[93, 94] with 100% sensitivity achieved in identifying the tumours that had
a local relapse in two independent studies.[93, 94] However, the assays used had a relatively
low specificity (40%),[94] and contamination of margin samples by mutated DNA derived
from cells leaking from the tumour could not be excluded.[93, 94] In a recent study by Bilde et
al., immunohistochemistry was used to analyse surgical specimens from 16 consecutive OSCC
patients with surgical margins deemed negative.[49] Histologically normal epithelium
adjacent to oral carcinomas showed upregulation of both p53 and p16, but with very little
overlap.[49] It was not possible to conclude whether the observed changes represented early
malignant changes or simply a reaction to cellular stress.[49] In case-control comparisons using
immunohistochemistry, p53 appears to have problems with respect to marker sensitivity,
which may be due to the presence of mutations not resulting in protein overexpression.[83,
93, 95-97] Ultimately, there remains insufficient evidence to determine whether p53 alterations
can be used as predictive markers to identify surgical margins at risk of local recurrence.
A number of studies have shown a correlation between p53 expression and early recurrence,
risk for secondary recurrence, metastatic spread and more aggressive disease progression.[49,
98] Studies involving immunohistochemical staining for the p53 tumour suppressor protein,
image cytometry of abnormal DNA content, and promoter methylation of the p16 tumour
suppressor gene have all attempted to establish potential markers for malignant progression.
[99-101] Inactivation of p53 has been associated with a reduction in post-surgical patient
survival in OSCC.[102, 103] Suprabasal p53 staining was found to be correlated with increasing
grades of dysplasia in a recent study by Vered et al.,[104] consistent with an earlier study by
Bortoluzzi et al.[104, 105] However, Cruz et al.[99] did not find a correlation between grade of
dysplasia and p53 expression, with Murti et al.[106] finding a similar level of p53 expression
in biopsies of patients who did or did not progress to OSCC; thus concluding that p53
expression was not predictive of the risk of malignant transformation. p53, in combination
Contemporary Issues in Head and Neck Cancer Management88
with p16INK4a and Ki-67 alteration, has been proposed as potential markers to define high
risk leukoplakia, with further validation in larger sample sizes required.[107]
Due to the many differences in study design, methodology and laboratory techniques, there
are currently conflicting reports regarding the value of p53 as a biomarker for the prediction
of relapse in HNSCC surgical margins. There is yet to be sufficient validated evidence on its
utility in adoption for predictive assessment of dysplastic progression.
The proto-oncogene eIF4E (eukaryotic initiation factor 4E) is a eukaryotic translation initiation
factor.[108] eIF4E regulates the translation of cap-dependent mRNAs, and an aberrant increase
in eIF4E shifts the balance in favour of translation of transcripts that promote cell proliferation
and malignancy.[96, 108] eIF4E protein is commonly elevated in HNSCCs,[109] and its
overexpression in surgical margins has been found in a number of studies associated with
increased risk of local recurrence.[96] In an investigation into the prognostic value of p53 and
eIF4E expression in laryngeal carcinoma surgical margins, Nathan et al. concluded that eIF4E
overexpression appeared to be a more sensitive indicator of recurrence, and suggested that it
may occur as an earlier event in the tumourigenesis process.[110] A recent study by Yi et al.
investigating the prognostic value of p53, eIF4E and cyclin D1 in laryngeal carcinoma surgical
margins found similar results, finding that eIF4E overexpression positivity of margins
displayed a greater sensitivity than the other two studied factors.[96] Ultimately, further
studies are still required to validate and assess the clinical utility of eIF4E in the surgical margin
assessment of HNSCC.
Other genes in the p53 family have also been analysed, such as p63, p73 (both structurally and
functionally related to p53) and CDK inhibitor (CDKI) p21. There is again insufficient data to
determine the predictive value of p63 and p73 in the progression of dysplastic HNSCC lesions,
and whilst general trends have been elucidated in the literature, there is no published data
that correlates p63 or p73 expression with the prediction of progression to HNSCC.[104, 111,
112] There are conflicting reports on the expression of p21 in the progression of dysplasia in
HNSCC, with Choi et al. concluding that whilst an increasing trend in p21 expression was
detected in histological progression, there was no significant correlation or progression to
OSCC.[113] Future studies aimed at assessing the p53 pathway as a whole may be beneficial
to further explore the mechanisms of its deregulation in dysplastic progression to HNSCC.
3.4. microRNA
There has been increasing evidence of the role of non-coding microRNAs (miRs) in the
regulation of fundamental processes such as cell cycle, differentiation and apoptosis; and by
extension, the impact of their dysregulation on the process of carcinogenesis.[114-117] MiRs
are single-stranded endogenous, non-coding RNA transcribed from DNA, ranging between
18 and 24 nucleotides in length. They have the ability to regulate expression of other genes on
a post-transcriptional level through various processes by degradation or repression of target
mRNA; influencing organ development, cell differentiation, proliferation, apoptosis and stress
responses.[118, 119] Recent studies have suggested that miRs may also regulate mRNA targets
through less stringent mechanisms, such as binding to non-complementary regions and
binding to sites located within the coding regions of transcripts.[120] Given their pivotal
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function as post-transcriptional regulators of gene expression, miRs affect almost every cellular
process; and have been implicated in numerous disease types, including cancer.[116, 119, 121]
The role of miRs in cancer development was first established by Calin et al. in a study that
reported a specific miR cluster (miR-15/16) was deleted and/or down-regulated in the majority
of chronic lymphocytic leukemia (CLL) cases.[122] The link to cancer was further strengthened
by the discovery that miR genomic positioning appeared to be non-random,[121, 122] and that
a significant number of miR genes were located at fragile sites (unstable regions that have been
shown to promote DNA instability in cancer cells) or genomic regions that have been linked
to cancers.[123] RAS, HMGA2, and MYC oncogenes have been identified as let-7 targets,
indicating significant tumour-suppressive importance for this family of miRs.[118, 123]
There have been many molecular studies investigating the expression and dysregulation of
miRs in HNSCC.[13, 115, 116, 124-126] Using a candidate-gene approach, most have attempted
to examine the role of expression and proposed targets of specific miRs in HNSCC cell lines
compared to normal samples.[13, 125-128] The underlying process by which miR deregulation
affects the process of transition from dysplasia to HNSCC has not yet been fully elucidated,
with a main impediment being the multifactorial aetiology of HNSCC and wide heterogeneity
of lesions. However, Zhang et al. reported that Dicer and Drosha, enzymes involved in
processing miRNA, were upregulated in salivary gland pleomorphic adenomas.[129]
In HNSCC, Li et al. found an increased level of miR-21 expression that was negatively
associated with low levels of tropomyosin 1 (TPM1) and phosphate tensin homologue (PTEN);
TSGs that mediate apoptotic and cell-cycle events.[126] In the same study, miR-21 was found
to facilitate anchorage-independent growth of HNSCC cells, partly through the down-
regulation of TPM1.[126] This finding has been validated in further studies observing elevated
miR-21 expression contribution to neoplastic phenotypes.[130, 131] It is pertinent to note that
most studies to date investigating miR expression profiles in HNSCC have used cancer cell
lines, and only a few have been in solid tumour samples.[13, 132] Cell lines may not reflect the
miR profiles of solid tumours, as particular culture conditions and clonal selection may
radically change miR expression.[128] Of the few studies which have selected specific miRs
for further investigation using patient samples, Childs et al. showed that miR-21 was also found
in neoplastic head and neck cells, and may have potential as a prognostic marker in HNC.[124]
To date, there are limited studies investigating the role of miRs in surgical margins.[47]
Santhi et al. analysed 72 miRs reported to be differentially expressed in OSCC and detected
decreased expression of miR-125a, miR-184 and miR-16 and an increased expression of miR-96
in both progressive oral mucosal samples and dysplastic surgical margin samples.[47]
Langevin et al. found miR-137 promoter hypermethylation to be associated with poor overall
survival in patients with HNSCC, but found no significant associations with surgical resection
margin positivity[133]. Further studies are required to define a broader set of miR profiles
within a wider range of surgical samples, and to correlate results with patient outcomes.
Ultimately, there remains insufficient evidence to determine whether these alterations could
be used as predictive markers to identify dysplastic progression to HNSCC.
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Despite the increasing number of studies into miR expression in HNSCC, there remain few
publications that have investigated the deregulation of miRs in the transition process from
dysplasia to malignancy. In an investigation of miR pre-cursors in oral leukoplakia (OL), Xiao
et al. found up-regulation of both miR-31 and its passenger strand (termed miR-31*).[134]
miR-31* was negatively associated with recurrent/newly formed OL, and they hypothesized
that miR-31* may play an important role during OL progression via the regulation of fibroblast
growth factor 3 (FGF3).[134] This was consistent with miR expression profile findings in a
prospective translational study by Lajer et al., who examined global miR expression in a series
of consecutive tumours and biopsies obtained from patients with OSCC and OPSCC.[128] Of
the one hundred and fourteen miRs differentially expressed between OSCC and normal
epithelium, the upregulation of miR-31 and downregulation of miR-375 were found to be the
most significant aberrations.[128] Thus there is evidence to suggest that the upregulation of
miR-31 may be an early event in the transition process from dysplasia to OSCC; however,
further elucidation of its role in the progression process and its predictive value still requires
further investigation.
Ultimately, whilst early results of molecular prognostic indicators such as LOH and eIF4E
appear promising, the routine use of these markers for HNSCC surgical resection margins
assessment is yet to be validated. Further research is required which can ideally integrate the
convenience of histopathology with the objectivity of molecular panel analysis, supported by
a distinct outline of clinical parameters, baseline data, and sufficiently sizable homogeneous
patient populations amenable to long-term follow-up.
4. Imaging techniques
It has now been established that molecular profiling of tissue changes enable clinicians to
“visualise” more of the disease, indeed diagnose altered tissue early. While macroscopic
changes may be detected under white light examination and tissue/cell level changes through
histopathology, molecular dysregulation may be identified using special imaging techniques.
While most current methods assess tissue in the plane parallel to the lesion, methods aiding
assessment in the vertical cross-section (plane perpendicular to the mucosal surface) are
required to detect lesions below the mucosal surface and evaluate submucosal tumour
invasion.[135]
All optical imaging techniques detect and analyse backscattered photons from mucosa.[135]
Visible light (400-700 nm) is used for conventional white light inspection, however shorter
wavelengths in ultraviolet (UV) and longer wavelengths in the near-infrared (NIR) regions of
the light spectrum can also be used for imaging. UV and blue light are absorbed by biomole‐
cules to produce fluorescence.[135] In order to detect targeted tumour cells, the tumour-
specific signal must be significantly discriminated from the non-specific background signals,
thus optimising the signal-to-background ration (SBR).[136] The visible light spectrum has
relatively short penetration depths useful for imaging (<100 µm) as it is mostly absorbed by
haemoglobin, and is significantly associated with a high level of nonspecific surrounding
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signals, resulting in a low SBR.[135, 136] NIR is less susceptible to tissue scattering and
haemoglobin absorption, yielding penetration depths >1000 µm through the mucosa and a
high SBR, with an optical imaging window of about 650-900 nm in which the absorption
coefficient is at a minimum.[135, 136]
Optical imaging techniques using Optical Fluorescence Imaging (OFI) and Narrow Band
Imaging (NBI) reflect tissue changes at the microscopic and molecular levels. Optical Coher‐
ence Tomography (OCT) and Angle-Resolved Low-Coherence Interferometry (a/LCI) non-
invasively provide information in the vertical and axial planes. Raman spectroscopy is a point
detection technique based on the inelastic scattering of light, also enabling molecular histo‐
pathological examination. Computed Tomography (CT) and Magnetic Resonance Imaging
(MRI) are methods traditionally used to detect carcinoma and metastasis (hence staging), and
assess treatment response, providing anatomical and physiological information. Positron
emission tomography (PET) is a true form of molecular imaging, opening the door for drug
delivery and molecular surgical guidance. Hybrid imaging methods, PET/CT and PET/MRI,
offer the best of both these imaging approaches. All these methods, collectively termed “optical
biopsy”, are non-destructive in situ assays of mucosal histopathologic states using the spectral
and spatial properties of scattered light to measure cellular and/or tissue morphology,
providing an instantaneous diagnosis.[135, 137]
4.1. Optical imaging
4.1.1. Optical coherence tomography
Optical Coherence Tomography (OCT) is based on the principle of low-coherence interfer‐
ometry.[135] It provides high resolution (~1-20 µm) cross-sectional images of tissue in situ,
higher than conventional ultrasound, MRI, or CT, and comparable to conventional histology
but being non-destructive, it aids real-time surgical diagnostics and an “optical biopsy” of the
tissue.[138] Initial success with this modality was with retinal pathology[139] and broncho‐
pulmonary diseases.[140] More recently, it has been deemed useful in diagnosing diseases of
the oropharynx/larynx and other oral tissues.[138, 141, 142]
OCT is similar to ultrasound B-mode imaging except that OCT uses light instead of acoustic
waves, measuring the echo time delay and intensity of backscattered light.[143] The system
uses NIR light, split into reference and sample beams, and plots the back-reflected light from
structures within the tissue against depth (up to 2-3 mm).[139, 143, 144] Since the velocity of
light is extremely high, optical echoes cannot be measured directly by electronic detection, but
instead uses low-coherence interferometry – the back scattered light waves interfere with the
reference beam and this interference pattern is used to measure the light echoes versus the
depth profile of the tissue in vivo.[144] OCT also uses fibre optic technology, allowing for low-
profile imaging to be performed through small optical fibres attached directly to a scalpel,
tissue probe, endoscope, or microscope.[144] The device is compact and portable.[144]
In healthy mucosa, the basement membrane can be easily identified at the junction of the bright
lamina propria and the darker epithelium, which is lost in the presence of invasive cancer.[145]
However, one study had inconsistent results, showing a deceptive change in the histological
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layers when compared to conventional biopsy of oral lesions (various anatomical sites).[138]
The authors also noted that OCT image analysis is unique, requiring special training, and
associated with a wide range of variability when interpreting its parameters (mainly epithe‐
lium thickness and status of basement membrane).[138] The authors previously aimed to
generate a bank of normative and pathological OCT data from oral tissues to identify cellular
structures of normal and pathological processes, thus creating a diagnostic algorithm.[146]
While OCT is useful for clinical detection of OSCC and OPML,[147] it also has potential in
evaluating surgical margins for MRD in HNSCC just as it has been proven useful in cancers
of other tissues such as breast,[148, 149] skin,[150, 151] vulva,[152] and prostate.[153]
4.1.2. Angle-resolved low-coherence interferometry
Angle-resolved low-coherence interferometry (a/LCI) is a light scattering technique which
isolates the angle scattering distribution from cellular nuclei at various tissue depths.[137] In
doing so, it is able to provide biomarkers based on morphology that are highly correlated with
the presence of dysplasia.[137] It measures the angular intensity distribution of light scattered
by a tissue sample, quantifying subcellular morphology as a function of depth in the tissue.
[137] For each depth layer, signatures from cell nuclei are extracted by collecting and process‐
ing the angular scattering signal using a Mie theory-based light-scattering model to produce
measurements of average nuclear diameter with submicron-level accuracy.[137] Studies that
have investigated the use of a/LCI have confirmed that neoplastic tissue transformation is
accompanied by an increase in the average cell nuclei size,[137, 154-156] thus detecting
potentially malignant lesions as well as malignant lesions. The diameter of a non-dysplastic
epithelial cell nucleus is typically 5-10 µm, while dysplastic nuclei can be as large as 20 µm
across.[157] When this is optimized to 11.84 µm for the classification of tissue health, a/LCI
yields a sensitivity of 100%, specificity of 84%, overall accuracy of 86%, positive predictive
value of 34% and negative predictive value of 100% in oesophageal epithelium in vivo.[137,
155] This technique has been studied in animal models, ex vivo human studies, and more
recently in in vivo studies, predominantly associated with cases of Barrett’s Oesophagus (which
is associated with an increased risk of oesophageal adenocarcinoma) and oesophageal
epithelium.[137] The system is portable and the probe can be used through the accessory
channel of a standard endoscope, thus providing surgical guidance.[137]
a/LCI could have a role in assessing surgical margins in HNSCC by assessing size of nuclei in
the margins although currently there are no studies that have investigated this.
4.1.3. Optical fluorescence imaging
The basis of optical imaging techniques is the ability of photons to travel through tissue and
interact with tissue components.[158] Fluorescence is the property of certain molecules to
absorb light at a particular wavelength and to emit light of a longer wavelength after a brief
interval called fluorescence lifetime.[158] Fluorescence spectroscopy, a major form of optical
imaging, is a non-invasive diagnostic tool that evaluates the biochemical composition and
structure of tissue autofluorescence (AF).[159] It is relatively simple, fast, accurate, and can aid
Contemporary Assessment and Management of Head and Neck Cancer Surgical Margins
http://dx.doi.org/10.5772/60066
93
in real-time cancer detection.[159] While microscopic imaging systems for intraoperative
surgical margin assessment based on endogenous contrast or AF are useful, high resolution
of the diseased tissue is limited to a small field of view, making it difficult to survey the entire
surgical excision margin intraoperatively.[20] Extrinsic approaches are more effective, which
use fluorescent dyes detected by probes.[20] The signals can also be integrated into the white
light image, which enables real-time intraoperative visualisation.[20] OFI is advantageous and
convenient as it can be used intraoperatively for surgical guidance in resecting malignant tissue
and for pathological sampling.[160] Various devices implementing OFI, both commercially
available as well as those developed by researchers, using visible light or NIR, with or without
excitable dyes, have been investigated mostly in breast cancer,[160, 161] but is now being tested
in HNSCC as well.[162-166]
Francisco et al.[159] recently showed that fluorescence spectroscopy could discriminate
between oral mucosa, injury, margins, and areas of recurrence, using a homemade fluorescence
spectroscopy system, at 406 nm wavelength [159] without using injectable dyes, and providing
macroscopic visualisation of affected and unaffected tissue. The VELscope™ and Identafi™
are commercially available tools that use the principles of AF and tissue reflectance to
discriminate between normal and abnormal tissue. These tools are described below in order
to illustrate loss of AF (LAF) and diascopic fluorescence as indicators of tissue change, which
provide the clinician with additional information aiding diagnosis. Miyamoto et al. investi‐
gated intraoperative molecular imaging (multispectral fluorescence images) to identify
tumour extensions in a murine HNC model.[167] They reported 86% sensitivity and 100%
specificity in the diagnostic accuracy analysis compared to histology, the gold standard. They
also reported a 60-day improvement in survival rate when using molecular imaging during
surgery, compared to standard surgery (37% versus 5% respectively). Thus fluorescence can
be used both for diagnosis and for surgical guidance to improve patient outcomes.
The Visually Enhanced Lesion Scope (VELscope™; LED Medical Diagnostics Inc., Barnaby
Canada) uses direct tissue AF to enhance oral mucosal abnormalities.[7] An external light
source, in this case blue light excitation between 400-460 nm, is used to excite endogenous
fluorophores (typically nicotinamide adenine dinucleotide (NADH) and flavin adenine
dinucleotide (FAD)) in the oral epithelium and collagen cross-links in the underlying stroma,
which absorb the extrinsic photons and emit lower energy photons which appear clinically as
fluorescence.[168-173] Since each fluorophore is associated with specific excitation and
emission wavelengths, changes in tissue architecture and concentrations of fluorophores (as
in the case of mucosal abnormalities and neoplastic development) results in altered absorption
and scattering properties of the tissue,[7] with decreased tissue AF being reported in OED and
mucosal inflammation.[68, 169, 174] Under the VELscope™, normal oral mucosa appears pale
green when viewed under a filter while abnormal tissue exhibits LAF and appears dark.
While the VELscope™ has assisted in the detection of OED and OSCC not visible by conven‐
tional oral examination (COE) warranting tissue biopsy and aiding in demarcating margins,
[68, 175] clinicians have been advised to use the VELscope™ in conjunction with COE as LAF
may also be displayed in tissues with mucosal inflammation.[176] Complete diascopic
fluorescence, wherein tissues display normal fluorescence pattern with the application of
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pressure, can differentiate inflammatory lesions from neoplastic lesions.[176] However, the
challenge of completely blanching tissues and inter-operator variation in the interpretation of
partial blanching (i.e. low specificity and variable sensitivity) grades the VELscope™ as a
useful clinical tool for clinically visualising abnormalities but not an accurate discriminator of
the condition of the mucosa under inspection.[176] Nevertheless, a recent clinical study
suggested the use of a decision making protocol incorporating the VELscope™ in routine
general dental practice allows for the detection of additional oral mucosal lesions requiring
specialist referral.[177]
The Identafi™ (DentalEZ, PA, USA) is a multispectral screening device which uses direct
fluorescence as well as tissue reflectance to visualise intraoral tissues by incorporating three
different lights which are to be used sequentially.{#1120;Bhatia, 2013 #729} The light emitting
diode (LED) white light enables superior visualisation of oral tissues but cannot differentiate
between OPML and other more benign abnormalities of the oral mucosa, in a manner similar
to that displayed by Microlux/DL™.[7, 178] Visualisation of oral mucosa under violet light
(405 nm wavelength) through the accompanying photosensitive filter glasses, assesses the AF
properties of tissue, with normal mucosa exhibiting natural fluorescence and abnormal tissues
displaying LAF in a similar fashion to VELscope™.[7] Despite the dubious sensitivity and
specificity of this wavelength of light,[173] areas of LAF visualised were often larger than what
was clinically visible which might be due to the visualisation of deeper neovascularisation and
stromal changes that accompany lesion progression, thus having a potential application in the
determination of surgical margins for lesion excision.[163, 164] The green-amber light (545 nm
wavelength) uses the concept of reflectance spectroscopy to characterise the connective tissue
vasculature.[7] The process of carcinogenesis involves angiogenesis resulting in altered
vascular morphology and it has been suggested that these tissue changes can be used to
determine the prognosis of oral lesions, enabling the differentiation between benign lesions
and OPML.[7, 179-181] Reflectance spectroscopy uses light within the absorption spectrum of
haemoglobin (400-600 nm) which would reflect the degree of angiogenesis in the tissue. A
significantly reduced reflectance spectra is observed in OSCC and OPML due to greater light
absorption from increased microvasculature density and oxygenated haemoglobin content in
neoplastic tissue.[7]
The underlying principles have enormous potential for application. Ongoing clinical trials by
our group have shown excellent lesion visibility compared to COE under incandescent light.
Violet light examination provided improved lesion visibility compared to COE, and improved
visualisation of lesion borders and slight increase in lesion size compared to incandescent and
white light. It also has a high level of clinical utility for evaluating inflammatory pathology.
However, a high level of clinical experience is required to interpret the results of AF exami‐
nation as the violet light displays low sensitivity for detection of OED. The green light helps
uncover subtle vascular and inflammatory patterns providing additional clinical information.
Both these technologies highlight the usefulness of detecting LAF and diascopic fluorescence,
however, additional information is required to diagnose the tissue change. Molecular studies
in this area aid in our understanding of the phenomena of AF, LAF and diascopic fluorescence
in oral tissues, enabling more informed use of such devices and superior interpretation of
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changes in AF patterns. One study in oral cancer patients showed that all their tumour samples
(confirmed by histopathology) had displayed LOH intraorally when a simple hand-held
device, similar to the VELscope™, was used.[68] Molecular analysis in this study on margins
with low-grade or no dysplasia showed a significant association between LAF samples and
LOH at 3p and/or 9p, which is strongly associated with tumour recurrence after tumour
removal.[68] Furthermore, this study found that LAF extended beyond the clinical visible
lesion, and these areas displayed dysplasia/cancer on histology and/or genetic alterations
associated with molecular risk, thus showing that the VELscope™ can distinguish between
dysplasia and normal oral mucosa.[68]
4.1.4. Narrow band imaging
Narrow Band Imaging (NBI; Olympus Medical Systems Corporation, Tokyo, Japan) utilises
the concept that the depth of light penetration is dependent on its wavelength to enhance
mucosal surface texture and underlying vasculature.[182, 183] The spectral bandwidth of the
filtered light is narrowed.[183] The system has two modes, white light and NBI.[7] In NBI
mode, only blue light (400 – 430 nm) and green light (525 – 555 nm) are emitted in parallel
which make blood vessels in the superficial mucosa appear brown, and the deeper larger
vessels in the submucosa appear cyan.[183] Blue light (centred at 415 nm) penetrates shallowly
and corresponds to the peak absorption spectrum of haemoglobin, while green light (centred
at 540 nm) penetrates deeper.[183] In NBI mode, inflammatory lesions have an ill-demarcated
border and can be differentiated from neoplastic lesions which appear as areas with scattered
dark spots and a well-demarcated border.[184, 185] These scattered dark brown spots repre‐
sent superficial blood vessels; interpapillary capillary loops (IPCL).[7] Visualisation of the
vasculature, as well as the degree of dilation, meandering, tortuosity, and calibre of IPCLs all
indicate the true extent of lesions and severity of pathology, thus guiding the position of biopsy
and resection margins.[184, 186-188] Takano et al.’s[184] IPCL classification for oral mucosa is
tabulated in Table 3. It has been recommended that lesions with Types III and IV IPCL patterns
must always be biopsied.[189] The presence of keratinised tissue can pose a hindrance to
optimal visualisation of the lesion itself.[7]
Gono  et  al.[183]  used  NBI  in  colonoscopy  and  upper  gastrointestinal  endoscopy  and
concluded that magnified NBI enhanced the capillary pattern and the crypt pattern on the
mucosa,  which  are  useful  features  for  diagnosing  early  cancer.[190]  Later,  Muto  et  al.
reported that carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites can be
clinically  recognised  using  magnified  NBI  endoscopy,  confirming  the  usefulness  of
evaluating in situ angiogenesis  in  solid tumours in  the head and neck region.[191,  192]
Yoshida et al. validated the use of NBI with magnifying endoscopy in oesophageal lesions.
[193] A case report by Katada et al. showed the usefulness of NBI combined with gastroin‐
testinal endoscopy (GIE) in detecting OSCC in the floor of the mouth.[187] Further case
reports and investigations also supported the use of NBI in the oropharynx,[194] nasophar‐
ynx,[195,  196]  hypopharynx,[197]  larynx,[198]  and oesophagus.[199]  Its  use  in  determin‐
ing tumour size and margins in gastrointestinal cancers of the bile duct,[200, 201] duodenal
papilla,[202] stomach[203,  204] was also investigated, all  with encouraging results boast‐
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ing higher sensitivities and specificities than the current detection method used at the time.
All these studies hailed NBI as a method with improved detection and diagnostic accura‐
cy of cancers in areas that are difficult to examine, and critically allowing for early diagnosis,
having an impact  on treatment  options,  quality  of  life  and patient  survival.[205]  It  was
considered that NBI would develop into a useful tool in the future pre-, intra-, and post-
operative endoscopic assessment of neoplastic lesions in the upper aerodigestive tract.[206]
Type Description/Features
I
⋅ Normal mucosa
⋅ Regular brown dots – when loops are perpendicular to the surface of the mucosa
⋅ Waved lines – loops are parallel
⋅ Study by Yang et al.[189] – 17% frequency of dysplasia in these lesions, hence remain cautious and
utilise clinical judgement as well
II ⋅ Non neoplastic and inflammatory lesions, but dysplasia present most of the time⋅ Dilated and crossing IPCL pattern
III ⋅ Non neoplastic lesions, but dysplasia is almost definitely present⋅ Elongated and meandering IPCL pattern
IV
⋅ Neoplastic lesions
⋅ Large vessels IPCL pattern destruction
⋅ Presence of angiogenesis
Table 3. Summary of IPCL classification for oral mucosa by Takano et al.[184]
In a multicentre, prospective, randomised controlled trial (n = 320), Muto et al.[207] found that
NBI detected superficial cancer more frequently than white light imaging in both the head and
neck region (100% vs 8%) and the oesophagus (97% vs 55%). They reported a sensitivity and
accuracy of 100% and 86.7% in the detection of superficial cancer in the head and neck region
using NBI, and 97.2% and 88.9% in the oesophagus, respectively.[207] Piazza et al.[208] showed
that 27% (26 of 96) of patients with OSCC and OPSCC had a diagnostic advantage by applying
NBI and high definition television (HDTV) compared to white light and HDTV. In a later study,
[209] they concluded that NBI and HDTV were of value in defining superficial tumour
extension, in the detection of synchronous lesions in the pre-/intra-operative settings, and in
post-treatment surveillance for early detection of persistence, recurrence, and metachronous
tumours.
Fielding et al. combined white light and AF to the bronchoscopic and laryngoscopic assess‐
ments of head and neck cancer patients, and reported improved sensitivity but low specificity,
increasing the number of unnecessary biopsies.[210] A later study combined AF and NBI for
the detection of mucosal lesions during panendoscopy in head and neck cancer patients, and
reported higher specificity than when using AF or white light alone, thus directly impacting
on patient management.[211]
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A recently published systematic review by Vu & Farah[212] on the efficacy of NBI for detection
and surveillance of OPML analysed data from a prospective cohort study by Piazza et al.,[209]
and a retrospective cohort study by Yang et al.;[213] both of which aimed to evaluate the
efficacy of NBI endoscopy compared to WL in oral mucosal examination. Vu & Farah con‐
cluded that based on available evidence, there is a demonstrable improvement in the ability
of NBI visualization to stage tumours, assess margins and detect synchronous, metachronous
and recurrent lesions compared to visualization using broadband WL.[212]
A prospective study by Nguyen et al. utilized white light (WL), NBI and AFAF to inspect the
oral cavity, larynx/hypopharynx and bronchus of 73 patients with known HNSCC, patients
with SCC of unknown primary origin, and surgically treated HNSCC patients requiring
panendoscopy for suspected recurrent disease.[211] The authors found a significant improve‐
ment in the detection of moderate dysplasia or worse by NBI compared to WL, and that the
combined use of AF and NBI had significant implications upon mapping and guiding the
surgical resection borders of three assessed oral cases.[211] This study demonstrated increased
specificity with NBI for the detection of mucosal lesions.[211]
While OFI and NBI can detect tissue and molecular changes in a localised region, imaging
modalities such as Computed Tomography (CT) and Magnetic Resonance Imaging (MRI)
provide anatomical information, including nodal involvement and metastasis which influence
staging and treatment protocol employed. Ultimately, multimodal imaging can provide
additional diagnostic information than white light illumination or a single imaging modality
alone.[214, 215]
Both CT and MRI involve 3D sectional imaging and have extremely high diagnostic value.
[216] CT scans require ionising radiation (with shorter scan times) while MRI does not but has
a longer scan time.[216] CT is currently the most commonly used modality for head and neck
imaging, and can improve delineation of soft tissue pathologies with intravenously adminis‐
tered contrast media,[216] however MRI provides the most detailed view of soft tissues and
is routinely used to visualise such tumours.[216]
4.2. Molecular imaging
Molecular imaging modalities have the potential to be indispensable in every aspect of cancer
care, from early detection to staging, drug delivery, molecular surgical guidance and treatment
response.[20, 217, 218] Oncological molecular imaging is defined as the non-invasive imaging
of distinctive cellular and sub-cellular events in malignant cells.[20, 219] Molecular imaging
probes target the production of genetically determined biomolecules by cancer cells by
displaying these directly in or on individual malignant cells, in the extracellular matrix, or cells
in the vicinity such as T cells, macrophages, dendritic cells, fibroblasts or endothelial cells.[158,
220, 221] For example, probes paired with positron emitters and novel target-specific anti‐
cancer drugs could be quantitatively imaged by PET, providing information on tumour
biology, guiding drug development, and furthering personalized medicine.[14, 17] Diseased
tissue may also be detected through this imaging modality based on hypoxia [222, 223] or pH
changes.[17, 224] It is clearly useful to detect changes at the cellular and molecular level rather
than rely on anatomical characteristics alone which is commonly the case at present.[20]
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Tumours may be able to be characterised without biopsies or surgery, and allow for accurate
staging, re-staging and drug response monitoring, paving the way towards true personalised
medicine.[20] Molecular imaging modalities may also be used for intraoperative surgical
guidance and evaluation of surgical margins, thus improving outcomes.[20]
4.2.1. Raman spectroscopy
Raman spectroscopy is a non-invasive technique that can analyse the molecular composi‐
tion of a tissue, enabling surgeons to identify, examine and determine the quality of the
tumour’s molecular margins.[145] It is based on the phenomenon that intramolecular bonds
cause light to scatter in a manner that is both measurable and predictable, albeit for a very
short time constituting <1 part per million of the total reflected light.[145] Point detection
techniques can be used to collect molecular information during endoscopy with optical fibre
probes, and they have the potential to be extended to imaging.[135] Raman spectroscopy
produces  inelastic  light  scattering  (returning  photons  have  longer  wavelength  than  the
incident  photons)  and diffuse  NIR photons  (photons  that  return after  several  scattering
events  and  are  useful  for  measuring  fine  pathological  structures)  which  aid  molecular
histopathologic  examination.[135]  It  is  performed  by  illuminating  tissue  with  NIR  pho‐
tons that are absorbed by the vibrational/rotational nodes of molecular bonds associated
with  chemical  functional  groups  specific  to  mucosal  proteins,  lipids,  and  nucleic  acids.
[135,  225,  226]  Some  of  these  photons  are  then  inelastically  scattered,  forming  detailed
spectral  patterns  that  can  be  reduced  to  the  principal  components  using  multivariate
statistics. However, the Raman effect is much weaker than fluorescence and can be easily
obscured by fluorescence from the tissue or optical fibre itself.[136]
Shim et al. demonstrated the use of CCD detector in collecting Raman spectra in vivo in the
gastrointestinal tract.[227] Molckovsky and colleagues showed that Raman spectroscopy
could be used to distinguish between adenomatous and hyperplastic polyps in the colon, with
100% sensitivity, 89% specificity, and 95% accuracy when used in vivo.[228] Haka et al. used
Raman spectroscopy to examine breast tissue in vivo, and reported perfect sensitivity and
specificity when using their diagnostic algorithm.[229] They highlighted the feasibility of using
it for real-time intraoperative margin assessment during partial mastectomy surgery, which
could be similarly used for intraoperative margin assessment in HNSCC cases. Stone et al.
examined biopsy specimens of laryngeal mucosa using Raman spectroscopy and conventional
histopathological analysis, and reported 92% sensitivity and 90% specificity for Raman spectra
generated over 30 seconds in the diagnosis of invasive cancer (compared to reference spectra
generated from histopathologically normal mucosa).[230] In membranous vocal cord speci‐
mens, Lau et al. reported 69% sensitivity and 94% specificity for invasive carcinoma using
Raman spectra recorded over 5 seconds.[231]
Spatially offset Raman spectroscopy (SORS) has been shown to be an effective tool in recov‐
ering Raman spectra from up to several millimetres beneath the surface of turbid media.[232]
Keller et al. found that, using source-detector separations of up to 3.75 mm, SORS can detect
sub-millimetre-thick tumours under a 1mm normal layer, and tumours at least 1 mm thick can
be detected under a 2 mm normal layer using the Monte Carlo simulation model of breast
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tumour margin analysis.[232] Other recent developments within Raman spectroscopy include
surface enhanced Raman spectroscopy (SERS), coherent anti-Stokes Raman spectroscopy
(CARS), and stimulated Raman scatters (SRS),[165, 233] which could all have applications in
HNSCC margin analysis. Visualising molecular information using Raman spectroscopy has
also been shown to aid in identifying patients with prostate cancer who are at risk of cancer
progression from those with no evidence of disease.[234]
Raman spectroscopy provides an objective analysis of the tissue’s molecular structure
compared to the ex vivo histopathological analysis and grading based on tissue morphology.
It may provide a more clinically relevant measure of the tumour margin on which to guide
surgical excision. It has been possible to stage and grade malignancies from a spectral meas‐
urement on the surface of bladder tissue using Raman spectroscopy.[235] Representative
reference spectra need to be developed by analysing a large cohort of histologically diagnosed
mucosal lesions, against which spectra captured in vivo can be compared and leading to
algorithms that can quickly produce a diagnosis.[145]
4.2.2. Positron emission tomography and hybrid technologies
PET provides a 3-D image of the functional processes in the body, wherein (18F)-fluorodeox‐
yglucose (18F-FDG), a glucose analogue, is commonly used as the radiopharmaceutical
delivering the positron-emitting radionuclide (tracer), thus reflecting tissue metabolic activity
by regional glucose uptake, with cancer cells exhibiting increased use of glucose.[20, 236] 18F-
FDG PET highlights metabolic differences between malignant and healthy cells and is the first
true molecular imaging modality.[20]A hand-held PET probe to detect high-energy gamma
rays during breast cancer surgery has been developed for intra-operative evaluation of tumour
localisation and margin status.[162] PET is limited in its use due to high cost, use of ionising
radiation, and relatively low spatial resolution (it is difficult to detect small tumours (<1 cm)
using this hand-held probe).[20, 136] Since PET on its own provides low anatomical informa‐
tion, it is commonly used in conjunction with CT, and more recently, with MRI which has the
advantage of greater soft tissue contrast and fewer artefacts.[14] The PET/MRI hybrid imaging
technology combines the functional sequences of MR with the molecular information of PET
to provide information about tumour biology and microenvironment [237] – hence the best of
both worlds.
A number of studies have evaluated the effectiveness of PET/CT versus PET/MRI in HNSCC.
Many studies have found no significant difference between diagnostic capability and anatomic
localisation of lesions as detected by both modalities,[238-243] however, there is agreement for
tailored use of PET/MRI in the head and neck region since higher soft tissue contrast would
aid in diagnosis.[238, 242, 244, 245] Kanda et al. found that PET/MRI and PET/CT had equal
sensitivities and specificities, and both these were more sensitive compared to MRI alone but
less specific, when investigating these modalities in HNSCC.[244] Kubiessa et al.[239] showed
that PET alone had the highest sensitivity while MRI alone showed best specificity when
comparing PET/CT to PET/MRI in patients with HNSCC. Evangelista et al. evaluated contrast-
enhanced CT (ceCT) with PET in HNSCC cases and found this to be particularly adept at
diagnosing small lymph node metastases in positions usually difficult to interpret in the head
Contemporary Issues in Head and Neck Cancer Management100
and neck region.[246] Lee et al. found PET/MRI to have acceptable accuracy in T staging
compared to endoscopic ultrasound and even higher accuracy (although not statistically
significant) than PET/CT in predicting N staging, demonstrating its value as preoperative
diagnostic imaging tool in HNSCC.[245] PET/CT has been deemed useful in staging, identifi‐
cation of second primaries, and monitoring in the head and neck region aiding treatment
planning.[216, 236, 244, 245, 247]
Hybrid technologies can be used to assess treatment response.[246, 248, 249] Adkins et al. found
that PET/CT is better than CT in evaluating tumour response to cetuximab in patients with
incurable HNSCC.[248] PET/CT has also exhibited high sensitivity to detecting distant
metastases, assessing the response to chemotherapy or chemoradiation treatment and in
predicting outcome.[246] PET/CT can be used post-therapeutically to assess treatment
response, detect residual/recurrent tumours, and exclude distant metastases.[15] “Activatable
molecular probes” or “smart” probes may be used to elicit a change in signal upon enzymatic
activity or in response to specific biomolecular interactions.[20, 220] These allow very high
signal-to-background ratios compared to conventional targeted contrast agents, and lead to
the possibility of imaging intracellular targets.[220] Nguyen and Tsien summarise that the use
of these fluorescent-labelled molecularly targeted probes would provide real-time, intraoper‐
ative distinction of the molecular edge between cancer and adjacent normal tissue, and could
aid in discerning and preservation of vital structures such as nerves during surgery.[218]
Bhatnagar et al. reviewed the use of different PET tracers in hybrid imaging modalities such
as PET/CT and PET/MRI to detect and monitor biomarker status to assess effectiveness of
therapy in patients with HNSCC.[250] They suggest that treatment strategies could be
modulated and adapted by comparing an initial baseline measurement of biomarker expres‐
sion before treatment to measurements taken during therapy, thus strategically addressing
treatment response.[250] Some examples of biomarkers that may be used in this instance are
tissue hypoxia, cell proliferation and apoptosis, and epidermal growth factor receptor (EGFR)
status.[250] Examples of PET tracers that may be used in relation to biomarkers of response to
therapy are described below.
4.2.3. Tumour hypoxia
Hypoxia has been established as an indicator of poor prognosis in HNSCC patients, causing
radiation  resistance  in  tumour  cells  by  preventing  irreversible  damage  to  DNA by free
radicals  induced  by  ionising  radiation  (oxygen  is  required  for  the  production  of  free
radicals), thus allowing DNA repair and tumour cell survival.[251, 252] The critical partial
pressure of oxygen below which solid tumours resist radiation therapy is about 10-15mm
Hg.[252] In comparison, three times the amount of radiation needed to kill tumour cells in
normoxic conditions is required to achieve the same in hypoxia. Hypoxia mapping can be
performed with the use of molecular imaging to identify tumours that would benefit from
hypoxia-reducing treatments.[250]
Fluoromisonidazole  (FMISO)  has  been  investigated  widely  as  a  PET  imaging  agent  in
HNSCC.[253-256]  It  has  been  shown  that  FMISO  and  FDG  uptake  do  not  necessarily
correlate, thus representing different tumour properties, with high uptake of FMISO before
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radiation therapy indicative of locoregional treatment failure and associated poor prognosis.
[250, 255, 256] Nevertheless, FMISO may be used in HNSCCs to delineate hypoxic tumour
volumes as an indicator to escalate radiation doses.[257-260] The key challenge though is
that tumour hypoxia is a dynamic process with a constant change in relative contribution
of acute and chronic hypoxia to the total hypoxic volume.[250] One study showed just 46%
correlation between two sequential FMISO scans, just 3 days apart, in 20 HNSCC patients.
[261]  A  smaller  study  with  7  HNSCC  patients  found  correlation  between  hypoxic  vol‐
umes  on  sequential  scans  in  only  three  patients.[262]  Further  research  is  required  to
investigate  the  normal  variation  in  FMISO uptake  and  changes  in  tumour  oxygenation
kinetics  prior  and during  therapy,  before  FMISO imaging  can  clinically  guide  hypoxia-
mediate intensity modulated radiation therapy (IMRT).[250, 259, 263]
Fluorine 18 fluoroazomycin arabinoside (FAZA) is also a hypoxia-specific PET agent that clears
the blood more rapidly than FMISO, thus producing a higher target-to-background signal
ratio.[264] Fluorine 18 fluoroerythronitroimidazole (FETNIM) is in theory a stronger indicator
of hypoxia than FMISO due to its greater hydrophilia and better pharmacokinetics.[265] Both
agents show promise as hypoxia radiotracers, but further research is needed, especially in
comparison to FMISO.
Radioactive copper–labelled diacetyl-bis-(N4- methylthiosemicarbazone), or Cu-ATSM, is a
neutral lipophilic compound that can permeate cell membranes.[250] In hypoxic conditions,
Cu-ATSM molecules are reduced and negatively charged, while they wash out rapidly from
normoxic cells, thus selectively accumulating in hypoxic cells resulting in a high SBR.[266] It
has been shown that Cu-ATSM showed a significant difference in its uptake in HNSCC patients
with residual or recurrent tumour compared to those without, which was not reflected in FDG
uptake.[267] Others have shown that Cu-ATSM may be used to identify hypoxic subvolumes
for IMRT.[268]
4.2.4. Tumour cell proliferation
While radiation therapy and chemotherapy can lead to a rapid decrease in the rate of cellular
proliferation in responding tumours, which precedes a decrease in tumour size, accelerated
tumour cell repopulation is an indicator of underlying radiation resistance and hence,
treatment failure.[251, 269] Early identification of tumour cell repopulation as part of response
assessment through imaging can identify target areas for dose escalation.[250] 3'-Fluoro-3'
deoxythymidine (FLT)-PET is used widely to assess cellular proliferation, and unlike FDG, is
only taken up by actively dividing cells and not surrounding inflammatory cells, allowing for
specific detection of cellular division and subsequent dose escalation in these areas.[270, 271]
Changes in the intensity of FLT uptake can be used to reflect cellular response to treatment,
even prior to changes in tumour volume.[251, 271] However, FLT does not distinguish between
benign and malignant abnormal cervical lymph nodes because its uptake by the germinal
centres of reactive lymph nodes leads to a low positive predictive value.[272]
4.2.5. Apoptosis
Chemotherapy and radiation therapy rely on apoptosis to induce tumour cell death. Radiation
resistance and treatment failure can result from mutations that lead to uncontrolled cellular
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proliferation and dysregulation of apoptotic mechanisms.[273] Technetium 99m (99mTc)–
labelled annexin V is a protein that binds to a major phospholipid constituent of cell mem‐
branes and has been investigated for imaging apoptosis in various malignancies including
HNSCC.[274] The difficulty of radiolabeling annexin V with fluorine 18 has led to the devel‐
opment of other such tracers such as 18F-ML- 10 (2-[5-fluoro-pentyl]-2-methyl-malonic acid)
(Aposense; Petach Tikva, Israel). This is a novel small-molecule probe designed to allow
visualisation of apoptosis related cellular alterations, useful for differentiating between
apoptotic and necrotic cells.[275]
4.2.6. Amino acid transport and protein synthesis
Carbon 11 (11C) methionine is a PET tracer that has been investigated to assess amino acid
transport and accelerated protein synthesis in malignant tissue.[276] 11C-methionine allows
for effective visualisation of HNSCC, demonstrating a good correlation with FDG demon‐
strating similar sensitivities and specificities for tumour detection, but does not distinguish
between histological grade.[277, 278] It has been shown that there is a decline in 11C-methio‐
nine uptake at tumour sites with histology-confirmed complete treatment response in HNSCC
patients, in comparison with sites of residual tumour tissue after radiation therapy.[279] Early
decrease of 11C-methionine uptake correlates to final tumour volume reduction seen at MRI
at the conclusion of treatment in HNSCC patients, suggesting that 11C-methionine can be used
for early treatment adaptation.[280] Conversely, Nuutinen et al. showed a substantial early
decline in 11C-methionine uptake in HNSCC patients after radiation therapy, but the rate of
decrease in tracer uptake was comparable between patients with disease recurrence and those
with preserved local control.[281] At present, there is no clear role for 11C-methionine in the
imaging of HNSCC.[250]
Fluorine 18 fluoroethyltyrosine (FET), an amino acid analogue that is taken up by tumour cells
through amino acid transport systems, has shown high diagnostic accuracy in patients with
brain tumours, but has lower sensitivity (64-75%) when compared to FDG (89-95%) in the
evaluation of HNSCC, making it unsuitable to replace FDG in the initial assessment of HNSCC
despite superior specificity (90-100%) than FDG (50-79%).[282-285] FET could still have a role
in differentiating between residual tumour tissue and inflammatory tissue after therapy.[250]
4.2.7. Cell membrane synthesis
Choline is incorporated with phospholipids during cell membrane synthesis.[286] A prelimi‐
nary study[287] using 11C-choline in HNSCC patients found it to be just as effective as FDG
for detecting malignant head and neck tumours with PET, however, another study[288] did
not find 11C-choline PET/CT to be superior to FDG PET/CT for the detection of recurrent
HNSCC.
While this is useful, carcinogenesis and transformation of tissue in HNSCC involves elaborate
modification of numerous biomarkers. It would be more useful to assess the overall imbalance
in biomarker regulation rather than rely on one marker alone. This considerably complicates
the process of molecular diagnosis and analysis through imaging and requires further research.
OFI techniques can be used intraoperatively, in conjunction with information from pre-
operative MRI, CT or PET, providing a more holistic knowledge of macroscopic and molecular
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level tissue alterations, enabling ideal surgical guidance.[289-291] This will ultimately improve
patient outcome by decreasing MRD in surgical margins.
5. Conclusion
Methods for early detection, molecular assessment of margins and surgical guidance, and
assessment of treatment response are instrumental to changing the rate of local recurrence and
resultant reduced prognosis in patients with HNSCC by enabling personalised medicine.
There are a number of biomarkers that alter expression as tissue transforms. These can be used
to assess MRD in surgical margins. Furthermore, optical and molecular imaging techniques
can be used to identify molecular changes in biomarker expression, enabling immediate
intraoperative decisions on extent of lesion and margin status, reducing the need for repeat
surgery and the risk of recurrence. Multimodal imaging will provide more information about
diseased tissue, enabling the surgeon to visualise the tumour in terms of its molecular extent
and not simply its visual extent (whether with white light or fluorescence). Further research
into molecular biomarkers as potential targets for “smart” probes for assessment of MRD in
surgical margins is required to enhance current molecular imaging modalities which have
applications pre-operatively to delineate lesion location and volume, intra-operatively to
assess surgical margins and for surgical guidance, and post-operatively to assess treatment
response. Research is also required to assess projected improvements in overall recurrence
rates following introduction of these technologies to reveal whether these technologies have
improved outcomes in practice.
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